Brought to you by 
Genexine, Kalbe establish 40/60 JV in Indonesia
10 Jun 2022
Executive Summary
Korean biotech Genexine Inc. and Indonesia's PT Kalbe Farma TBK set up an Indonesian joint venture that will use Genexine's technology and Kalbe's production and distribution expertise within the ASEAN region to create protein therapeutics.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genexine, Kalbe establish 40/60 JV in Indonesia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice